Elcelyx Forms Its Own Fund To Lead $20 Million Series C Financing
This article was originally published in The Pink Sheet Daily
Executive Summary
The money raised will bring the San Diego company’s total to $43 million and will be used to advance its delayed-release metformin, NewMet, through Phase IIb and into a partnership. The cash also will fund an efficacy trial for over-the-counter dietary supplement Lovidia.
You may also be interested in...
Financings Of The Fortnight Looks To The High-Tech Sector For New Life-Science Capital Sources
Plus news on recent financings by Elcelyx, Jounce Therapeutics, Retrophin and e-Therapeutics.
Dissidents Win Some, Lose Some In Amylin Showdown
Shareholder vote rocks the Amylin boat, but only very gently.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.